a random-effects study-level meta-analysis, and a meta-regression analysis of covariates of interest. We examined the risk of publication bias using the fail-safe test. Results: In a pooled analysis of studies from the 3 separate meta-analyses, we identified a total of 51 LAI treatment arms, including 13,071 individuals (mean age=38.8 ± 6.2, 60.5 ± 11.9% male, illness duration=12.1 ± 5.7 years, mean total PANSS score=74.3 ± 7.8). The mean planned follow-up duration was 71.5 ± 37.0 (range=24-154) weeks, and the defined daily dose (DDD) of LAI treatment was 1.1. The pooled weighted relapse rate in a random effects model was 28% (95% CI=24-31%), being 22% (95% CI=15-30%) in RCTs (mean duration= 66.2 wks), 33.0% (95% CI=24-43%) in mirror image studies (mean duration= 55.4 wks), and 30% (95% CI=26-34%) in naturalistic cohort studies (mean duration= 79.4 wks). In a meta-regression analysis, RCT design (p=0.04), and industry sponsorship (p=0.03) were associated with lower relapse rates on LAI treatment, whereas studies conducted in Europe (p=0.03) or North America (p<0.01), and longer duration of follow-up (p<0.01) were associated with greater relapse rates. In the fail-safe test, we found that we would need 4,629 studies to bring the p Value>α, suggesting low risk of bias. Discussion: About one in four individuals receiving LAI treatment relapsed according to study definitions, suggesting that this is a relatively common phenomenon, even during assured medication adherence. At the study level, no major differences were observed in terms of sociodemographic characteristics, type of drugs, mean drug daily dose, or baseline severity at study entry in relation to relapse rate in individuals treated with LAIs. The relapse rate though was lower in RCTs, which could reflect a difference in the patient population participating and/or the nature of observation in LAI RCTs. These results suggest either that the examined study design, illness severity and treatment related covariates are limited to identify potential mediators and moderators of BAMM, or that the data about the covariates at the study level was not precise enough to detect clinical characteristics associated with BAMM. Given the relative frequency of BAMM, future research should explore potential mediators and moderators of the failure to maintain response to antipsychotic treatment even during periods of assured adherence. Neurobiological markers, which may be more closely related to the pathophysiology of BAMM, and individual participant data meta-analyses, which can identify clinical predictors with greater precision, should be the next steps.
T235. SELF ASSESSMENT OF SOCIAL
Background: Impairments in self-assessment are commonly found in people with schizophrenia and impairments in introspective accuracy (IA) predict impaired functional outcome. previous studies have suggested mis-estimation of cognitive and functional skills predict impairment in everyday functioning at least as much as ability scores. In this study, we examined self-assessment of social cognitive ability and related these self-assessments to assessments of social cognition from informants, to performance on tests of social cognitive ability, and to everyday outcomes. The difference between self-reported social cognitive abilities and informant ratings was our measure of IA. Methods: People with schizophrenia (n=135) performed 8 tests of social cognitive abilities. They also rated their social cognitive abilities on the Observable Social Cognition Rating Scale (OSCARs). High contact informants also rated social cognitive ability and everyday outcomes, while unaware of the patients' other scores. Social competence was also measured with a performance-based assessment and clinical ratings of negative symptoms were also performed. Results: Patient reports of their social cognitive abilities were uncorrelated with performance on social cognitive tests and with three of the four domains of everyday functional outcomes. IA, in specific overestimation of performance compared to informant ratings, predicted impaired everyday functioning across all four functional domains. IA scores predicted functional outcomes even when the influences of social cognitive performance, social competence, and negative symptoms were considered in regression models. Thus, self-assessment of social cognition had a relatively specific impact social outcomes. Discussion: Mis-estimation of social cognitive ability was a more important predictor of social and nonsocial outcomes in schizophrenia than performance on social cognitive tests. These results suggest that consideration of IA is critical when attempting to assess causes of everyday disability and when implementing interventions aimed at disability reduction.
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